Statin use and pancreatic cancer risk in two prospective cohort studies | Zendy

Tsuyoshi Hamada | Zendy; Natalia Khalaf | Zendy; Chen Yuan | Zendy; Ana Babić | Zendy; Vicente MoralesOyarvide | Zendy; Zhi Rong Qian | Zendy; Jonathan A. Nowak | Zendy; Kimmie Ng | Zendy; Peter Kraft | Zendy; Douglas A. Rubinson | Zendy; Meir J. Stampfer | Zendy; Edward L. Giovannucci | Zendy; Charles S. Fuchs | Zendy; Shuji Ogino | Zendy; Brian M. Wolpin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Statin use and pancreatic cancer risk in two prospective cohort studies

Author(s) -

Tsuyoshi Hamada,

Natalia Khalaf,

Chen Yuan,

Ana Babić,

Vicente MoralesOyarvide,

Zhi Rong Qian,

Jonathan A. Nowak,

Kimmie Ng,

Peter Kraft,

Douglas A. Rubinson,

Meir J. Stampfer,

Edward L. Giovannucci,

Charles S. Fuchs,

Shuji Ogino,

Brian M. Wolpin

Publication year - 2018

Publication title -

journal of gastroenterology

Language(s) - English

Resource type - Journals

eISSN - 1435-5922

pISSN - 0944-1174

DOI - 10.1007/s00535-018-1430-x

Subject(s) - medicine , statin , pancreatic cancer , prospective cohort study , hazard ratio , cancer , cohort study , proportional hazards model , confounding , oncology , confidence interval

Statins, 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, are common lipid-lowering agents and may reduce the risk of several cancer types including pancreatic cancer. However, the association between statin use and pancreatic cancer risk has not been fully evaluated in prospective studies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research